CSL (AU:CSL) has released an update.
CSL reports a robust financial performance with its full-year net profit after tax (NPAT) rising to $2.64 billion, marking a 25% increase on a constant currency basis. This growth is primarily attributed to the exceptional performance of CSL Behring, particularly in immunoglobulin sales and the successful launch of HIZENTRA’s 50mL pre-filled syringe. The company anticipates a continued upward trajectory with projected NPATA of $3.2 billion to $3.3 billion for FY25, signaling a prosperous outlook.
For further insights into AU:CSL stock, check out TipRanks’ Stock Analysis page.
